600+ sources. One page. See who else covered it.
The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
[Liberian Observer] The Ministry of Health and its partners have concluded the 2026 National Health Review Conference with what health experts describe as one of the country's most consequential…
[This Day] Abakaliki -- The Vice Chancellor of David Umahi Federal University of Health Sciences (DUFUS), Ebonyi State, Professor Jesse Uneke, has said that Nigeria is losing over 600,000 people…
[Premium Times] At the heart of the discussions was a persistent financing problem: healthcare providers struggle to access affordable, long-term capital, while lenders and investors often require…
WHO Sierra Leone Second Quarter 2026 Results Newsletter sharkahm@who.int Tue, 11/08/2026 - 12:00 From strengthening maternal health services and disease prevention programmes to advancing emergency…
Vaderis Therapeutics’ bet that a type of treatment developed for cancers could work for a rare blood disorder is paying off. The 13-person Swiss startup raised $152 million in a Series B to run a ...
Experts are now supervising treatment, with acute nutritional deficiencies also detected among children